Albendazole Treatment of Human Hydatid Tissue
Authors:
- 1 January 1997
- journal article
- Published by Taylor & Francis in Scandinavian Journal of Infectious Diseases
- Vol. 29 (2) , 165-167
Abstract
The effect of albendazole was studied in 12 patients with cystic hydatid disease (CHD) of the liver. Six patients received albendazole continuously for 6 months, while 6 patients received albendazole for 6 courses of 4 weeks with a 2 week drug-free interval between cycles. The continuous therapy proved successful, with stable involution at the follow-up at 24 months, while the patients treated with discontinuous therapy showed improvement or relapse. In our experience, continuous therapy was more effective and can be considered to be a suitable alternative or percutaneous therapy in uncomplicated hydatid liver disease, as an initial treatment.Keywords
This publication has 12 references indexed in Scilit:
- Randomised controlled trial of efficacy of albendazole in intra-abdominal hydatid diseaseThe Lancet, 1993
- Therapy of human hydatid disease with mebendazole and albendazoleAntimicrobial Agents and Chemotherapy, 1993
- Diagnosis and treatment of human hydatidosis.British Journal of Clinical Pharmacology, 1993
- Percutaneous drainage versus albendazole therapy in hepatic hydatidosis: A prospective, randomized studyGastroenterology, 1993
- Management of hydatid disease of the liverPostgraduate Medical Journal, 1992
- Experience in the chemotherapy of severe, inoperable echinococcosis in manInfection, 1992
- Surgical Treatment of Hydatid Disease of the LiverArchives of Surgery, 1991
- Hydatid disease in ChinaParasitology Today, 1991
- Towards global control of cystic and alveolar hydatid diseasesParasitology Today, 1987
- A Review of Echinococcal DiseaseAnnals of Surgery, 1975